Financial Performance - The company achieved total operating revenue of 964,930,489.25 yuan in 2025, representing a year-on-year increase of 7.63% [1][2] - The net profit attributable to the parent company was 258,668,187.82 yuan, reflecting a year-on-year growth of 17.94% [1][2] - As of the end of the reporting period, total assets amounted to 2,709,928,593.09 yuan, an increase of 7.22% compared to the beginning of the period [1] - The equity attributable to the parent company reached 2,427,107,981.56 yuan, up by 7.94% from the start of the period [1] Business Development - The company has strengthened team building and market development, leading to growth in both total operating revenue and net profit [2] - Sales revenue from the main product, Nigulazole tablets, has maintained a rapid growth trend [2] - The company is actively advancing the research and development of new drugs, including the antidepressant JJH201501 and the anti-tumor drug JJH201601 [2] - The Phase III clinical trial for the antidepressant JJH201501 has been successfully completed, while the Phase IIa clinical trial for the anti-tumor drug JJH201601 is progressing smoothly [2] Incentive Mechanism - To establish and improve the company's long-term incentive mechanism, a restricted stock incentive plan for 2025 has been formulated and implemented [2] - The share-based payment expenses for the reporting period amounted to 23,506,400 yuan (unaudited, final data to be confirmed in the audited annual report) [2]

Core Viewpoint - The company reported a positive performance for the fiscal year 2025, with significant increases in both revenue and net profit, indicating strong operational health and growth potential in its product lines [1] Financial Performance - The company achieved total operating revenue of 965 million yuan, representing a year-on-year increase of 7.63% [1] - The net profit attributable to the parent company's shareholders was 259 million yuan, reflecting a year-on-year increase of 17.94% [1] Operational Highlights - The company has strengthened team building and market development, contributing to the growth in both revenue and net profit [1] - Sales revenue from the main product, Niquilol tablets, has maintained a rapid growth trend [1] Research and Development - The company is actively advancing the development of new drugs, including the antidepressant JJH201501 and the anti-tumor drug JJH201601 [1] - The Phase III clinical trial for the antidepressant JJH201501 has been successfully completed, while the Phase IIa clinical trial for the anti-tumor drug JJH201601 is progressing smoothly [1] Incentive Mechanism - To further establish and improve the company's long-term incentive mechanism, a restricted stock incentive plan for 2025 has been formulated and implemented [1] - The share-based payment expenses for the reporting period amounted to 23.5064 million yuan (unaudited, with final figures subject to the audited annual report) [1]

Group 1 - The company, Jibeier, announced a total operating revenue of 964,930,489.25 yuan for the year 2025, representing a year-on-year increase of 7.63% [2] - The net profit attributable to the owners of the parent company reached 258,668,187.82 yuan, showing a year-on-year growth of 17.94% [2]

Group 1 - The core viewpoint of the article highlights that Jibeier reported a revenue of approximately 965 million yuan for the fiscal year 2025, representing a year-on-year increase of 7.63% [1] - The net profit attributable to shareholders of the listed company was approximately 259 million yuan, reflecting a year-on-year increase of 17.94% [1] - The basic earnings per share reached 1.3 yuan, which is a year-on-year increase of 15.04% [1] Group 2 - The article also discusses a significant shift in the AI sector, noting that China's AI usage has surpassed that of the United States for the first time, leading to a surge in various sectors within the A-share market [1] - A well-known Wall Street analyst commented on China's computing power path, suggesting it disrupts traditional perceptions [1]

Financial Performance - Total operating revenue for 2025 reached ¥964,930,489.25, an increase of 7.63% year-on-year[2] - Net profit attributable to shareholders of the parent company was ¥258,668,187.82, up 17.94% compared to the previous year[2] - Basic earnings per share rose to ¥1.30, representing a 15.04% increase from ¥1.13 in the previous year[2] - The weighted average return on net assets increased by 0.53 percentage points to 11.04%[2] Assets and Equity - Total assets at the end of the reporting period were ¥2,709,928,593.09, reflecting a 7.22% increase from the beginning of the period[5] - Shareholders' equity attributable to the parent company increased by 7.94% to ¥2,427,107,981.56[5] Drug Development - The company is advancing the development of new drugs, including JJH201501 for depression and JJH201601 for oncology, with clinical trials progressing[5] Incentive Plans - The company implemented a restricted stock incentive plan for 2025, with share-based payment expenses amounting to ¥23,506,400 (unaudited)[5] Risk Awareness - The company emphasizes the importance of risk awareness, noting that the financial data is preliminary and subject to audit[6] Operational Performance - The company continues to strengthen team building and market development, contributing to overall positive operational performance[5]

Core Insights - The company reported a total operating revenue of 965 million yuan for the fiscal year 2025, representing a year-on-year growth of 7.63% [1] - The net profit reached 259 million yuan, showing a year-on-year increase of 17.94% [1] - Overall business performance during the reporting period was strong, driven by team building and market development efforts [1] Revenue and Profit Growth - The sales revenue of the main product, Niquilol tablets, maintained a rapid growth trend [1] - Both total operating revenue and net profit attributable to the parent company experienced growth [1] Research and Development Progress - The company is actively advancing the research and development of new drugs, including the antidepressant JJH201501 and the anti-tumor drug JJH201601 [1] - The Phase III clinical trial for the antidepressant JJH201501 has been successfully completed [1] - The Phase IIa clinical trial for the anti-tumor drug JJH201601 is progressing in an orderly manner [1]

Group 1 - The Qingdao Municipal Market Supervision Administration announced the proposed forced deregistration of Qingdao Jibeier Electric Co., Ltd. and 1,752 other companies due to their business licenses being revoked and not applying for deregistration for over three years [3] - The announcement is in accordance with Article 241 of the Company Law of the People's Republic of China and the Implementation Measures for the Forced Deregistration of Company Registration [3] - Interested parties, including creditors, have until May 4, 2026, to raise objections to the proposed deregistration through the National Enterprise Credit Information Publicity System or in written form [3]

Group 1 - The core point of the article is that as of February 13, 2026, the total number of shareholders for the company is 8,195 [2]

Core Viewpoint - The article discusses the current funding logic in the market, highlighting the significant movements of public funds in the technology sector, particularly in the semiconductor and biopharmaceutical industries, as they adjust their portfolios based on performance and valuation metrics [3][8]. Group 1: Public Fund Movements - Public funds have shown a notable shift in their holdings, particularly in the STAR Market, with the STAR 50 Index rising by 12.1% this year [3][4]. - The total market capitalization of STAR Market companies reached 10.4 trillion yuan, with the technology sector dominating, accounting for 62.1% of the total market cap [5][6]. - The semiconductor industry remains the core focus for fund allocation, with 12 companies in the sector having a market capitalization exceeding 10 billion yuan [9][11]. Group 2: Semiconductor Sector Insights - The market's pricing anchor for the semiconductor sector has shifted from "valuation expansion" to "performance realization," emphasizing the importance of actual earnings [13][14]. - Key drivers for future growth in the semiconductor sector include strong order backlogs, profit growth through acquisitions and expansions, and sustained price increases in advanced processes [13][14]. - Public funds have significantly increased their holdings in semiconductor materials, chip design, and equipment, with companies like ShenGong Co. seeing an 11% increase in fund holdings [15][21]. Group 3: Biopharmaceutical Sector Insights - The biopharmaceutical sector is a critical area for public funds, with major holdings in companies like BeiGene and United Imaging Healthcare, although the sector has faced a reduction in holdings for several key companies [24][26]. - The article notes that innovative drug companies are currently under pressure, with significant reductions in holdings observed in companies like BaiLi TianHeng and RongChang Biopharma [26][28]. - Despite the challenges, companies with strong earnings potential and innovative drug pipelines are still attracting interest from public funds, indicating a selective investment approach [35][40].

Core Viewpoint - The company has experienced a slight increase in shareholder numbers and net capital inflow, with stock performance slightly outperforming its industry sector [1][2]. Recent Events - As of February 10, 2026, the total number of shareholders for the company reached 7,927, an increase of 8 shareholders, representing a growth of 0.10%. The average market value per shareholder rose to 725,100 yuan. On February 11, the company reported a net capital inflow of 5.64 million yuan, accounting for 12.07% of the total trading volume, with the stock price increasing by 0.38% on that day. Additionally, the financing balance reached 226 million yuan on February 12, with a financing purchase amount of 11.91 million yuan, indicating an increase in market activity [2]. Stock Performance - Over the past 7 days, the company's stock price has increased by 1.68%, with a high of 29.16 yuan and a low of 28.49 yuan, resulting in a price fluctuation of 2.35%. The latest closing price on February 13 was 29.04 yuan, with a single-day increase of 0.41% and a trading volume of 6.81 million yuan, leading to a turnover rate of 0.12%. During the same period, the overall pharmaceutical and biological sector experienced a slight decline of 0.18%, while the chemical pharmaceutical sector rose by 0.07%, indicating the company's performance was slightly better than its industry [3]. Financial Report Analysis - According to the company's Q3 2025 report, the revenue for the first three quarters was 704 million yuan, reflecting a year-on-year growth of 9.52%. The net profit attributable to shareholders was 197 million yuan, with a year-on-year increase of 12.8%. However, the non-recurring net profit for Q3 alone was 46.81 million yuan, showing a year-on-year decline of 7.98%, which raises concerns about the sustainability of profitability. The gross margin remained high at 89.69%, and the debt ratio was 10.22%, indicating a relatively stable financial structure [4]. Institutional Viewpoints - According to Guosen Securities' investment strategy for the pharmaceutical and biological industry in February 2026, the valuation of the medical services and consumer sectors is at historical lows, with expectations for fundamental recovery in 2026. The report suggests focusing on undervalued stocks with improving performance. Although the report does not directly mention the company, it highlights opportunities within the chemical pharmaceutical sector, which is relevant to the company's main business [5].